Utsunomiya T, Shimada M, Shirabe K, Kajiyama K, Gion T, Takenaka K, Sugimachi K
Department of Surgery II, Kyushu University, Faculty of Medicine, Fukuoka 812, Japan.
Hepatogastroenterology. 2001 Jul-Aug;48(40):1088-93.
BACKGROUND/AIMS: None of the previous studies have compared the prognosis or clinicopathological factors between the patients with extrahepatic recurrence and those with intrahepatic recurrence of hepatocellular carcinoma after a hepatic resection.
The clinicopathological features and prognoses of patients with extrahepatic recurrence after a curative hepatectomy for hepatocellular carcinoma were investigated.
Twenty-three patients with extrahepatic recurrence had more advanced-stage hepatocellular carcinoma at the primary operation compared to 186 patients with intrahepatic recurrence. After adjusting for tumor size, the prognosis of the 2 groups were comparable. However, among the patients with hepatocellular carcinoma exceeding 5 cm in diameter, the number of patients whose plasma levels of des-gamma-carboxy prothrombin was higher than 2.0 AU/mL in the patients with extrahepatic recurrence (62.5%) was significantly more (P < 0.05) than that in the patients with intrahepatic recurrence (20.0%). On the other hand, the prognosis of the 13 patients with extrahepatic recurrence alone was significantly better than in the 10 patients with both intrahepatic and extrahepatic recurrences. The prognoses of the 3 patients who underwent a surgical resection for isolated extrahepatic recurrence were markedly better than that of the remaining 10 patients only treated palliatively.
If patients have tumors exceeding 5 cm in diameter and their plasma levels of des-gamma-carboxy prothrombin are higher than 2.0 AU/mL, more careful follow-up examinations than usual may thus be necessary in order to detect extrahepatic recurrence as early as possible. Furthermore, a surgical resection for the isolated extrahepatic recurrence of hepatocellular carcinoma is also recommended to produce long-term survivors.
背景/目的:既往尚无研究比较肝细胞癌肝切除术后肝外复发患者与肝内复发患者的预后及临床病理因素。
对肝细胞癌根治性肝切除术后发生肝外复发患者的临床病理特征及预后进行研究。
与186例肝内复发患者相比,23例肝外复发患者在初次手术时肝细胞癌分期更晚。在调整肿瘤大小后,两组预后相当。然而,在直径超过5 cm的肝细胞癌患者中,肝外复发患者血浆去γ-羧基凝血酶原水平高于2.0 AU/mL的患者数量(62.5%)显著多于肝内复发患者(20.0%)(P<0.05)。另一方面,仅发生肝外复发的13例患者的预后明显好于同时发生肝内和肝外复发的10例患者。3例因孤立性肝外复发接受手术切除患者的预后明显好于其余仅接受姑息治疗的10例患者。
如果患者肿瘤直径超过5 cm且血浆去γ-羧基凝血酶原水平高于2.0 AU/mL,则可能需要比常规更仔细的随访检查,以便尽早发现肝外复发。此外,对于肝细胞癌孤立性肝外复发,也建议进行手术切除以产生长期生存者。